For a large part of the world, where patients requiring Thrmbolysis cannot afford an expensive tPA treatment, Streptokinase is still the only viable option. The new recombinant Streptokinase (rSK) clone with a non Beta Lactum marker has been optimized for high level of protein expression using HCD fermentation and intelligent feeding techniques. An efficient Cell Lysis method has been developed by varying OD, and finally by designing an efficient protein refolding mechanism utilizing tools of hydrodynamic optimization. Chromatographic matrices are selected for highest binding efficiencies to deliver high level of purified rSK protein within shortest period of time. The idea behind the exercise is to express high purity rSK proteins at the maximum levels of protein for liter, resulting in a substantial cost reduction. Amongst Cardiovascular patients and number of people suffering strokes in urban and rural parts of India, at least 0.5% are at risk of suffering from myocardial infarction. This gives a potential of 6.0 million cases of thrombolytic treatment in India. Though for urban patients with higher economic capabilities, top preference would be a tPA drug followed by PCI, 60% of urban population and nearly 100% of the rural population are still candidates for streptokinase treatment. It is the key objective of this research to produce this life saving drug in an affordable manner for the millions of patients in South Asia and African region, who need it most.

Increase in expression levels, cell lysis, protein refolding and purification efficiency in recombinant Streptokinase using a non Beta Lactum marker for improved patient safety profile in thrombolysis applications for STEMI patients

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.